Alle Studien
Einschreibung auf EinladungPHASE2, PHASE3INTERVENTIONELL

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

This study is an extension of previous research, focusing on the long-term safety, how well it's tolerated, and the effectiveness of a medicine called tividenofusp alfa. This medicine is for children with a rare condition called Hunter syndrome, also known as Mucopolysaccharidosis Type II (MPS II). It's given through an IV (into a vein) and aims to help the brain and spinal cord. If you've already been part of related studies (DNLI-E-0002 or DNLI-E-0007) and meet certain conditions, you might be able to join this study. Participants will receive the medicine for up to 5 years, and for some, the original treatment they received in a previous study will remain unknown to everyone involved, ensuring fair evaluation.

Auf einen Blick

Status
Einschreibung auf Einladung
Phase
PHASE2, PHASE3
Sponsor
Denali Therapeutics Inc.
Einschreibeziel
99
Starten
20 Sep 2023
Geschätzte Fertigstellung
01. Juni 2027

Worum geht es in dieser Studie?

This study is an important next step for children living with Hunter syndrome, also known as Mucopolysaccharidosis Type II (MPS II). MPS II is a rare genetic condition that can affect many parts of the body, including the brain and spinal cord. Currently, treatments are available, but doctors are always looking for ways to improve care and find new options.

This particular study is testing a new investigational medicine called tividenofusp alfa (also known as DNL310). It's given through a drip into a vein (IV) and is designed to reach the brain and spinal cord. The main goal is to see how safe this medicine is over a longer period and how well children tolerate it. Researchers also want to understand how effective it is in managing the symptoms of Hunter syndrome long-term.

Because this is an 'extension study,' it's specifically for children who have already taken part in similar research studies (DNLI-E-0002 or DNLI-E-0007). By continuing to monitor these participants, researchers can gather valuable information about the medicine's long-term effects, which is crucial for helping to develop new treatments.

Wichtige Erkenntnisse

  • This study is for children with Hunter syndrome (MPS II).
  • It's testing a new medicine called tividenofusp alfa given by IV.
  • The main goal is to check its long-term safety and how well it works.
  • Only children who completed previous studies (DNLI-E-0002 or DNLI-E-0007) can join.
  • Participation could last up to 5 years, with regular clinic visits.
  • Sie können die Teilnahme jederzeit beenden.

Wer könnte berechtigt sein?

This study is for children who have already taken part in one of two previous research studies for Hunter syndrome (MPS II): Study DNLI-E-0002 or Study DNLI-E-0007.

If you were in Study DNLI-E-0002, you would need to have completed at least 49 weeks of that study and not have stopped the treatment early. If you were in Study DNLI-E-0007, you would need to have finished the entire treatment period in that study.

You would not be able to join this study if you have any serious or uncontrolled medical issues, or other health problems that the study doctors believe would make it unsafe for you to participate or would make it difficult to properly understand the study results.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Have you or your child been diagnosed with Hunter syndrome (MPS II)?
  2. Did you or your child participate in study DNLI-E-0002 and complete at least 49 weeks without stopping early?
  3. OR, did you or your child participate in study DNLI-E-0007 and complete the entire treatment period?
  4. Do you or your child have any uncontrolled medical conditions or other health issues that a doctor might consider too significant for study participation?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, you will receive the study medicine, tividenofusp alfa, for up to 5 years. The medicine is given through an IV (intravenously), meaning it will be delivered directly into your bloodstream, likely at a hospital or clinic. Throughout this period, you will have regular visits to the study site. During these visits, the study team will carefully check your health, how you are feeling, and any effects the medicine might be having. They will perform various assessments to monitor the safety of the treatment and see how well it's working. These assessments might include physical exams, blood tests, and other procedures relevant to Hunter syndrome. The exact schedule of visits and tests will be explained in detail by the study team.

Potenzielle Risiken und Vorteile

Taking part in any study has potential benefits and risks. The main potential benefit of this study is continued access to the investigational medicine tividenofusp alfa, which aims to help with Hunter syndrome. It contributes to understanding long-term safety and effectiveness, possibly leading to a new approved treatment. Potential risks could include side effects from the medicine, discomfort from IV infusions, or the time commitment for study visits. It's important to remember that you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Standorte (31)

  • UCSF Benioff Children's Hospital Oakland
    Verifizierte Postleitzahl
    Oakland, Vereinigte Staaten
  • Ann and Robert H Lurie Children's Hospital of Chicago
    Verifizierte Postleitzahl
    Chicago, Vereinigte Staaten
  • Hackensack Universitätsklinikum
    Verifizierte Postleitzahl
    Hackensack, Vereinigte Staaten
  • UNC Children's Research Institute
    Verifizierte Postleitzahl
    Chapel Hill, United States
  • Cincinnati Kinderkrankenhaus Medizinisches Zentrum
    Verifizierte Postleitzahl
    Cincinnati, Vereinigte Staaten
  • Children's Hospital of Philadelphia
    Verifizierte Postleitzahl
    Philadelphia, Vereinigte Staaten
  • The University of Texas Medical School at Houston
    Verifizierte Postleitzahl
    Houston, Vereinigte Staaten
  • Huntsman Cancer Hospital
    Verifizierte Postleitzahl
    Salt Lake City, Vereinigte Staaten
  • Sanatorio Mater Dei
    Verifizierte Postleitzahl
    Buenos Aires, Argentina
  • Universitair Ziekenhuis Antwerpen
    Verifizierte Postleitzahl
    Edegem, Belgien
  • UZ Brussel
    Verifizierte Postleitzahl
    Jette, Belgium
  • Hospital Clinicas Porto Alegre
    Verifizierte Postleitzahl
    Porto Alegre, Brazil

Häufige Fragen

What is Hunter syndrome (MPS II)?

Hunter syndrome is a rare genetic condition where the body can't break down certain complex sugars, leading to their build-up and causing various health problems, including developmental challenges.

What is tividenofusp alfa?

Tividenofusp alfa is an investigational medicine being tested in this study. It's designed to help the body process the substances that build up in Hunter syndrome, especially in the brain and spinal cord.

Wie wird das Medikament verabreicht?

The medicine is given through a drip into a vein, which is called an intravenous (IV) infusion.

How long will I be in this study?

If you join, you could receive the study medicine and be monitored for up to 5 years.

Can I join if I haven't been in a previous study?

No, this study is an extension and is only for children who have already participated in specific earlier studies (DNLI-E-0002 or DNLI-E-0007).

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "An Extension Study of the Long-Term Safety, Tolerability, an… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.